Tid Tittel Kategori Vedlegg
13.10.2026
08:00
Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update - -
09.09.2026
15:49
Zelluna ASA - Extraordinary General Meeting held on September 9, 2026 -
1
03.09.2026
12:22
Shareholder Disclosure Notification STORAKSJONÆR AKS -
01.09.2026
12:00
Zelluna ASA - Disclosure of voting rights of Extraordinary General Meeting STORAKSJONÆR AKS -
20.08.2026
07:00
Zelluna ASA: Resultater for andre kvartal 2026 RAPPORT RAP
2
20.08.2026
07:00
Zelluna ASA: Second Quarter 2026 results RAPPORT RAP
2
17.08.2026
13:11
Zelluna receives Independent Data Monitoring Committee recommendation to continue patient enrolment in ZIMA-101 - -
17.08.2026
13:11
Uavhengig Dataovervåkingskomité anbefaler å fortsette rekrutteringen av pasienter i ZIMA-101 studien - -
17.08.2026
10:13
Zelluna ASA: Notice of EGM - experienced international biotech executive proposed for election to the Board and Board member steps down -
2
17.08.2026
10:12
Zelluna ASA: Innkalling til ekstraordinær generalforsamling - erfaren internasjonal biotek-leder foreslått til styret, og styremedlem trer tilbake -
2
17.08.2026
07:45
Zelluna ASA: Innkalling til ekstraordinær generalforsamling - erfaren internasjonal biotek-leder foreslått til styret, og styremedlem trer tilbake - -
17.08.2026
07:45
Zelluna ASA: Notice of EGM - experienced international biotech executive proposed for election to the Board and Board member steps down - -
13.08.2026
12:00
Zelluna ASA: Invitation to Second Quarter 2026 Results Webcast Presentation - -
10.08.2026
09:46
Zelluna ASA: New share capital registered - -
06.08.2026
12:42
Zelluna ASA: Disclosure of large shareholding STORAKSJONÆR AKS -
04.08.2026
17:23
Zelluna ASA: Disclosure of large shareholding STORAKSJONÆR AKS -
04.08.2026
16:53
Zelluna ASA: Issuance of shares to Inven2 through set-off of settlement amounts under option and license agreement - -
13.07.2026
17:08
Zelluna doserer første pasient med ZI-MA4-1 i fase 1-studien ZIMA-101 - -
13.07.2026
17:08
Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial - -
30.06.2026
10:12
Zelluna ASA tildelt NOK 16 millioner i tilskudd fra Forskningsrådet - -
30.06.2026
10:12
Zelluna ASA awarded NOK 16 million Research Council of Norway grant - -
29.06.2026
13:03
Zelluna ASA: Mandatory notification of trade - Return of lent shares following Private Placement INSIDEHANDEL INS
1
29.06.2026
09:59
Zelluna ASA: New share capital registered - -
29.06.2026
08:30
Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities - -
29.06.2026
08:30
Zelluna ASA aktiverer The Royal Marsden som det andre kliniske senteret for ZIMA-101, og utvider kapasiteten for klinisk gjennomføring - -